Potassium Iodide: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026🚩 Report this page

Potassium Iodide

Active ingredient · 3 therapeutic classes

Sold as Kali iodatum · KALI IODATUM 1X

GB MHRAUS FDA

Drug class: Expectorants
Availability: Over-the-counter
Routes: Oral
Markets covered: 2
Products on record: 7
FDA reports (12 mo): 107

R05CAExpectorants S01XAOther Ophthalmologicals V03ABAntidotes

Overview

Potassium Iodide is an active pharmaceutical ingredient in the Expectorants group (R05CA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	5	May 15, 2026
US United States	FDA	2	December 16, 2025

GBUnited Kingdom· MHRA

5 products

Uses

GBOfficial regulatory label· revised December 5, 2025[1]

NUTRYELT is used as part of an intravenous nutrition regimen, to cover basal or moderately increased trace element requirements in parenteral nutrition. NUTRYELT is indicated in adults only.

How to take

GB

USUnited States· FDA

2 products

Uses

USOfficial regulatory label· revised December 16, 2025[2]

**

How to take

USOfficial regulatory label· revised December 16, 2025

Drug interactions

Known interactions involving Potassium Iodide. Select one for details. This list is informational and not a complete interaction checker.

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]MHRA (UK) · PL144340022 · revised December 5, 2025
[2]FDA DailyMed · 15eb7796-9787-45… · revised December 16, 2025 [PDF]
[3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised December 5, 2025[1]

The following adverse reaction(s) have been reported during post-marketing experience of trace elements solutions. The frequency is not known (cannot be estimated from the available data). System organ class (SOC) MedDRA Preferred Term GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Pain at the application site Cases of hypersensitivity reactions including fatal anaphylactic reactions have been reported in patients receiving IV iron-containing products.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

GBOfficial regulatory label· Warnings and precautions· revised December 5, 2025[1]

The solution should be used after an accurate control of the patient clinical and biological parameters. Blood manganese levels should be regularly monitored in case of prolonged artificial nutrition: dose reduction may be necessary or NUTRYELT infusion should be stopped if manganese levels rise into the potentially toxic range (please refer to appropriate reference ranges).
Particular attention must be paid when the product is given to patients with reduced biliary excretion, since it could interfere with the biliary elimination of manganese, copper and zinc, leading to accumulation and overdose. NUTRYELT should be used with caution in patients with impaired renal function as excretion of some trace elements (selenium, fluoride, chromium, molybdenum and zinc) may be significantly decreased.
In patients with renal, hepatic impairments or mild cholestasis the posology should be adapted. In patients undergoing medium to long-term parenteral nutrition, there is an increased occurence of iron, zinc and selenium deficiency. In such circumstances, when necessary, the dosage should be adapted with the use of an extra supply of solutions, which contain only these individual components.
For patients receiving repeated blood transfusions, a risk of iron overload can occur. Parenterally administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic/anaphylactoid reactions.
The risk is enhanced for patients with known allergies including drug allergies. Chromium deficiency leads to a decrease in glucose tolerance, which improves after chromium supplementation. As a consequence in diabetic patients on insulin medication, relative overdose of insulin and consecutive hypoglycemia may occur.
Therefore controls of the blood glucose levels are recommended and re-adjustment of the insulin doses may become necessary. g. iodine antiseptics) are administered concomitantly. e. essentially “sodium free”. e. essentially “potassium-free”.

This is not medical advice. Consult a qualified healthcare professional.